The alkyloid compound ellipticine derived from the berrywood tree is a topoisomerase II poison that is used in ovarian and breast cancer treatment. In this study, we report the identification of ellipticine derivatives and their tetracyclic angular benzopyridoindole analogues as novel ATP-competitive inhibitors of the protein kinase CK2. In vitro and in vivo assays showed that these compounds have a good pharmacologic profile, causing a marked inhibition of CK2 activity associated with cell cycle arrest and apoptosis in human cancer cells. Further, in vivo assays demonstrate antitumor activity in a mouse xenograft model of human glioblastoma. Finally, crystal structures of CK2-inhibitor complex provide structural insights on the molecular basis of CK2 inhibition. Our work lays the foundation for development of clinically useful CK2 inhibitors derived from a well-studied scaffold with suitable pharmacokinetics parameters. Cancer Res; 70(23); 9865-74. Ó2010 AACR.
Introduction
Protein kinases represent major therapeutic targets and several kinase inhibitors have demonstrated powerful clinical activity in pathologies in which the target kinase is dysregulated.
Protein kinase CK2 plays critical roles in cell growth, cell differentiation, apoptosis, and oncogenic transformation (1, 2) . CK2 has been found dysregulated in many cancers and its dual function in promotion of cell growth and in suppression of apoptosis may be particularly relevant to its oncogenic potential (3) . The recent association of aberrant CK2 expression with unfavorable prognostic markers in prostate cancer (4) and in acute myeloid leukemia (5) supports the direct implication of CK2 in tumor formation and recurrence. Indeed, CK2 is now considered as a promising therapeutic target, supporting the development of chemical inhibitors. Consequently, several classes of CK2 inhibitors have been reported showing various efficacy and specificity. Quercetin, emodin, 4,5,6,7-tetrabromo-1-benzotriazole (TBB), and indoloquinazolin derivative (IQA) are representative of main classes of ATP-competitive CK2 inhibitors (6, 7) . Other families were also described, such as anthraquinone-related compounds, condensed polyphenolic, 7-substitued indoloquinazoline derivatives, and 2,8-difurandicarboxylic acid derivatives (8) (9) (10) (11) . However, so far, only a single report described a CK2 inhibitor (CX-4945; Cylene Pharmaceuticals) disclosing in vivo efficacy (http://www. cylenepharma.com/cylene/pr_1230934977). Thus, broadening the availability and diversity of CK2 inhibitors is warranted.
We have identified ellipticine and benzopyridoindole derivatives as new CK2 inhibitors. Ellipticine and its derivatives exhibit antitumoral properties and are established chemotherapeutics (12) , acting either by distinct or common mechanisms of action. First, their intercalation in doublestranded DNA interferes with DNA replication or DNA transcription (13) . Second, ellipticine induces topoisomerase II-mediated transient DNA double-strand breaks, which have been identified as the primary cellular target of the drug (14, 15) . A third mechanism involves DNA adduct formation after P450 (CYP)-mediated activation of ellipticine in target tissues (16) . Several studies have also reported apoptosis induction by ellipticine involving the p53 tumor suppressor protein (17) (18) (19) . Finally, protein kinase inhibition may also represent a novel mechanism involved into ellipticine effect. Cdk2-dependent p53 phosphorylation is selectively inhibited by ellipticine and 9-hydroxyellipticine (20) . Ellipticine derivatives have also inhibitory activity on c-Kit (21) .
Here, we report that ellipticine and its benzopyridoindole derivatives are in vitro and in vivo ATP-competitive CK2 inhibitors displaying antitumoral activity. We provide a rationale basis for the mode of action of these compounds on the basis of the crystal structure of CK2a-inhibitor complexes. Knowing that ellipticine displays good pharmacokinetics criteria, this new class of inhibitors is a source of attractive leads for further optimization.
Material and Methods

Chemical libraries
The Institut Curie-CNRS library (6,560 compounds) and The Prestwick Chemical Library (1,120 compounds) were screened for CK2 inhibitors. Active compounds in the primary screen were retested from freshly made solutions.
Cell culture
HeLa (human cervical adenocarcinoma), U373 (human glioblastoma), MCF-10A (human mammary epithelial cells), MESSA, and MESSA Dx5 (myosarcoma) cell lines were obtained from the American Type Culture Collection (ATCC) during 2005. Cells were cultured and stored according to the supplier's instructions and used at passages 5 to 20. Briefly, cells were routinely cultivated in Dulbecco's medium (Invitrogen Life Technologies, Inc.) supplemented with 10% (v/v) fetal calf serum (BioWest), except for MCF-10A cells that were maintained in a 1:1 mixture of Dulbecco's modified Eagle's medium and Ham's F-12 medium supplemented with 5% horse serum, L-glutamine, 25 ng/mL human recombinant EGF, 100 ng/mL cholera toxin, 10 mg/mL insulin, and 0.5 mg/ mL hydrocortisone. Cells were last tested in July 2009 through cell morphology monitoring, growth curve analysis, and contamination checks.
Automated screening
Automated screening of chemical libraries was performed in 96-well plates using the automated platform of the CMBA (centre de Criblage pour Mol ecules Bio-Actives, Grenoble) screening facilities as described in the study of Prudent et al. (22) .
CK2 phosphorylation assays
Compounds were tested in a radiometric CK2 assay performed in a final volume of 18 mL containing 1 mL of compound or equivalent amount of dimethyl sulfoxide (DMSO) as control, 3 mL of CK2a (36 ng), and a mixture containing 100 mmol/L of peptide substrate (RRREDEESDDEE), 10 mmol/L MgCl 2 , and 100 mmol/L [g-32 P]-ATP (6,000 Ci/ mmol). Assays were performed at room temperature for 5 minutes before termination by the addition of 60 mL of 4% trichloroacetic acid. Incorporation of 32 P in the peptide substrate was determined as previously described (23) .
Protein purification and crystallization
A truncated active form of the catalytic a subunit of human CK2 (CK2a DC ) was expressed in Escherichia coli and purified as described in the study of Ermakova et al. (24 The final models were obtained after several rounds of alternate manual building with coot (28) and maximum likelihood refinement with Refmac5 of CCP4 (29) , and using data in all available resolution range. The final refinement statistics are summarized in Supplementary Table S1 . Pymol was used to generate structure figures. The structure factors and coordinates are deposited in the Protein Data Bank (PDB) under the accession numbers: 3OWJ, 3OWK, and 3OWL.
Kinase selectivity profiling Kinase selectivity of compound 18 was assessed using a panel of 57 recombinant protein kinases. The assays were performed at 10 mmol/L ATP in the presence of 10 mmol/L inhibitor using the Kinase profiler panel service (Millipore). Inhibition, expressed as the percent of activity determined in the absence of inhibitor, was calculated from the residual activity measured in the presence of 10 mmol/L inhibitor.
Cellular CK2 activity assay
Cellular CK2 activity was assayed as previously described (22, 30) . Briefly, HeLa cells were transfected with a chimeric yellow fluorescent protein-based CK2 activity reporter (pEYFPc1-SbS). Phosphorylation status of the reporter was measured using the monoclonal antibody anti-GFP/yellow fluorescent protein (Roche, ref. 1814460) at 1/1,000 and the goat anti-mouse HRP as secondary antibody (Sigma, ref. A4416).
Murine xenograft tumor assay
All experimental procedures adhered to our local ethical committee (Comit e r egional d' ethique pour l'Exp erimentation animale CREEA, Rhône Alpes, protocol no. 286). Female Harlan athymic nude mice (6-8 weeks) were inoculated subcutaneously into the right flank with 7.5 Â 10 5 U373 cells. When tumors reached AE50 mm 3 (volume ¼ length Â width Â height), animals were treated intraperitoneally 3 times weekly (every 2 days) for 2 weeks, with compound 19 (0.14 mg/100 mL per injection), or equivalent amount of DMSO (10% final) dissolved in PEG3350 22.5%, bovine serum albumin 0.45%. Body weight and tumor volume were determined twice a week. The experiment was terminated when tumor volume reached about 1,000 mm 3 . Results are presented as mean AE SEM.
Results
Discovery of new CK2 inhibitors by automated screening
So far, only few CK2 inhibitors display suitable pharmacokinetics criteria for in vivo investigations. To find new CK2 inhibitor scaffolds appropriate for in vivo uses, we screened the Prestwick Chemical Library. This library contains small molecules that were selected for their known bioavailability and safety in humans. The expectation was to identify hits that exhibit correct bioavailability and toxicity. These hits could provide good starting points for optimization program.
The library was screened in an automated luminescencebased kinase assay using human recombinant CK2a catalytic subunit ( Supplementary Fig. S1 ). Screening data were normalized and analyzed using an in-house software, TAMIS (Tool to Analysis and Manage Informations of Screening, Version 2.0; CEA, Grenoble, France). CK2 kinase inhibitory activity was determined at compound concentration of 10 mmol/L, using TBB and DMSO as positive and negative controls, respectively.
Up to 24 compounds belonging to several distinct structural families showed inhibition greater than 50%. Among those hits, ellipticine was the only drug with therapeutic indication in oncology. To identify more potent and selective CK2 inhibitors we performed a focused screen on ellipticine derivatives present in the Institut Curie-CNRS small molecule library ( Supplementary Fig. S1 ).
This led to the identification of benzopyridoindole derivatives (31, 32) . Radiometric CK2 kinase assay showed that 1, 8, 16, 18, 19 efficiently inhibited kinase activity in a dosedependent manner (Table 1) with IC 50 ranging from 0.31 to 1.5 mmol/L. This represents a 10-to 50-fold improvement in inhibitor potency when compared with our primary hit, ellipticine (in these conditions, IC 50 for ellipticine is 15.4 mmol/L ).
Chemical features of pyridocarbazole derivatives conferring CK2 inhibitory potency
To define the mode of CK2 inhibition by compound 1, we performed steady-state kinetic analysis ( Supplementary  Fig. S2 ). Lineweaver-Burk inhibition plots showed that CK2 inhibition by compound 1 is ATP competitive, with K i ¼ 0.86 mmol/L . Similar inhibitory potencies were found using CK2 holoenzyme (data not shown).
To gain insights into the features conferring inhibitory potency to compound 1, we tested a set of derivatives (Table 1) . Position 11 is relatively tolerant because substitution of methyl by hydrogen also leads to an active compound (compound 8) albeit less potent. In contrast, the free hydroxyl substituent at position 9 (compounds 1 and 8) is necessary because analogues bearing substituents other than hydroxyl (e.g., ether, ester) are less active or inactive even when assayed at 10 mmol/L (compounds 2, 4, 6, 7, 9, 10, 11, 12, 13, 14, 15, and 17).
Similarly, methylation of N2 is also not tolerated because compound 3 is inactive. In line with this observation, compound 5, which is fully substituted at positions 2, 9, and 11, is also inactive. Position 1 also seems to be relatively tolerant because replacement of lactam function (compound 8) by chloro group (compound 16) leads to active compound. Whether compounds 11, 12, and 13 are inactive because position 9 bears methoxy group or position 1 bears too bulky/hydrophobic substituents remains unknown.
Interestingly, although compounds 14, 15, and 17 bear methoxy groups at position 9, they display residual inhibitory potency. In the same trend, ellipticine is active (albeit at higher concentration). This observation indicates that unfavorable substitution at this important position can be counterbalanced by a network of favorable substitutions at other positions. We next investigated the features of the scaffold required for activity. Available pyridoindole (or g-carboline) derivatives bearing 3 fused rings exhibit poor or no activity (data not shown), meaning that 4 rings are necessary for optimal activity. We tested several available angular tetracyclic compounds related to intoplicine, which corresponds to antitumor agent inhibiting both topoisomerase I and II activities (33) . Surprisingly, 2 compounds belonging to benzo[g]-and benzo[e]-pyridoindole (or BgPI and BePI) (compounds 18 and 19, respectively) are potent CK2 inhibitors (Table 2 ). This indicates some tolerance into the scaffold of these new CK2 inhibitors.
In summary, regarding linear tetracyclic ellipticine derivatives, it appears that positions 9 and N2 are crucial for activity whereas positions 1 and 11 are relatively tolerant. Moreover, some variations into the scaffold of the molecule are allowed. Indeed, the angular tetracyclic analogues BgPI and BePI, which are structurally related to ellipticine, also exhibit significant CK2 inhibitory potencies.
Pyridocarbazole derivatives are multitarget compounds
Given the multiple targets of ellipticine and derivatives, we compared our structure-activity relationship data with published data (Supplementary Table S2 ), and on c-Kit (21) and topoisomerase II (15) . This analysis showed differences in structure-activity relationship according to the targets. For instance, whereas C1 substitution does not have a strong influence on topoisomerase II and CK2a activities, it is detrimental on c-Kit inhibitory potency when substituted by bulky groups. In contrast, N2 substitution is detrimental for CK2a inhibitory potency, but has no effect on topoisomerase II and cKit inhibition. N6 substitution has no influence on topoisomerase II, but is detrimental for c-Kit and CK2a inhibition. A common feature of the 3 targets is the presence of hydroxyl on position 9 in active compounds. Taken together, these observations indicate that distinct chemical requirements are necessary to selectively inhibit each of the 3 targets. CK2a and c-Kit kinase assays and topoisomerase IIa assay were performed at 10 mmol/L compound concentration. DNA intercalation assay was performed at 2.5 mmol/L compound concentration. 
Pyridocarbazole derivatives are cell-potent CK2 inhibitors
We assayed the inhibitory potencies of pyridocarbazole derivatives on living cells using a cell-based CK2 kinase assay ( Fig. 1) (22, 34) . In control HeLa cells, the CK2 activity reporter could be detected as a phosphorylated form (lower band in Fig. 1A ). When cells were treated with the known CK2 inhibitor TBB, the phosphorylated CK2 reporter form disappeared. Interestingly, 50 mmol/L ellipticine triggered a similar strong inhibition (Fig. 1A) . Other derivatives selected in the present work were found to be active in cells at similar or even lower concentrations (compounds 1, 8, 18, 19) ( Fig. 1B;  Supplementary Fig. S3 ).
Ellipticine and B[g/e]PI derivatives inhibit cell viability through cell cycle arrest and apoptosis
Because both ellipticine and CK2 inhibitors are known to affect cell survival, we measured cell viability of p53 wt HeLa cells after 48-hour treatment with TBB, ellipticine, or angular compounds 18 and 19 ( Fig. 2A) . B[g/e]PI derivatives reduced cell viability more efficiently than TBB (IC 50 of 2-10 mmol/L and 20 mmol/L, respectively). Interestingly, in p53 mut U373 glioblastoma cells, 5 mmol/L of pyridocarbazole derivatives was sufficient to decrease cell viability by 50% whereas in these conditions, TBB was not efficient (Fig. 2B) . U373 cells harbor a TP53 mutant isoform and are particularly resistant to drug-induced apoptosis. Other cancer cell lines such as wildtype or resistant myosarcoma cells (MESSA and MESSA Dx5, respectively) were highly sensitive to ellipticine and to a lower extent to compounds 18 and 19. Of note, the cell viability of the nontransformed MCF10A mammary epithelial cells was also strongly affected by ellipticine, whereas compounds 18 and 19 had a much weaker effect. As cell viability inhibition induced by ellipticine was reported to be correlated with cell cycle arrest (35), we measured the effect of ellipticine and B[g/e]PI derivatives on cell cycle distribution of HeLa and U373 cells (Fig. 3A) . Compared with vehicle-treated cells, 18-or 19-treated U373 cells exhibited a cell cycle arrest in G 2 /M phase. The treatment also caused an appreciable accumulation of the cells in sub-G 1 phase. We next assessed the effects of the compounds on the induction of apoptosis in U373 cells by (terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL). The results showed that 18 or 19 treatment results in the accumulation of TUNEL-positive cells. This effect was more pronounced with Ellipticine or staurosporine treatments (Fig. 3B) . Moreover, the same treatments induced an increase of caspase-dependent apoptosis attested by the activation of caspase 3/7 activity (Fig. 3C) .
Although these compounds are cell-potent CK2 inhibitors, we noticed that except for ellipticine, the active concentrations able to induce marked CK2 inhibition were higher than those required to induce cytotoxicity. Ellipticine is known as a multitarget agent, thus our selected active benzopyridoindole derivatives could, beside CK2a, affect other targets involved in cell viability. Indeed, when kinase selectivity of compound 18 was profiled, several kinases involved in cancer-related pathways such as Pim-1, Mnk2, and DARK1 were significantly affected (Supplementary Table S3 ).
Benzopyridoindole derivatives inhibit colony formation and tumor growth
To ascertain the potential therapeutic interest of compounds 18 and 19, we first tested their ability to inhibit colony formation using soft agar assay as an in vitro surrogate of tumorigenesis. U373 cells can grow without anchorage and form colonies in soft agar culture, reflecting their malignant properties. Both compounds 18 and 19 at a concentration of 5 mmol/L inhibited drastically colony formation (Fig. 4A) . In comparison, a weak inhibition of colony formation (10%) was observed in response to 50 mmol/L of TBB (data not shown).
Next, murine xenograft tumor assays were carried out to assess both toxicity and efficiency of compound 18, which showed the best inhibitory activities toward cell viability and colony formation. In mice treated with compound 18, we observed a significant reduction of tumor incidence, whatever the time point. Three weeks after first compound injection, mice injected with compound 18 had tumors that were 5 to 6 times smaller than those injected with DMSO (Fig. 4B) . Furthermore, mice were healthy after repetitive injections of the compound. They grew normally without significant weight loss. In addition, no obvious toxic effects were observed when the experiment was terminated and the tumors removed, indicating that compound 18 was relatively well tolerated at doses sufficient to induce antitumoral effect. 10 μmol/L 50 μmol/L 100 μmol/L Figure 1 . A, ellipticine inhibition of CK2 activity in living cells. HeLa cells transfected with a plasmid expressing a chimeric CK2 activity GFP-based reporter were incubated with the CK2 inhibitor TBB, ellipticine, or DMSO (as control) for 24 hours. Cell extracts were then analyzed by native electrophoresis and GFP was revealed by immunoblotting. The arrow indicates the CK2-phosphorylated form of the reporter. B, selected derivatives that were active in vitro were submitted to the cell-based CK2 activity assay as in A. þ, a significant decrease in the phosphorylated form of the CK2 activity reporter (lower band in A and in Supplementary  Fig. S3 ).
X-ray crystallographic structures of CK2-inhibitor complexes
To gain insights at the atomic level into the mode of action of these new inhibitors, we solved the structure of the truncated active form of CK2a in complex with pyridocarbazole and B[g/e]PI derivatives by X-ray crystallography: compound 1/CK2a at 1.85 A resolution, compound 18/ CK2a at 1.80 A resolution, and compound 19/CK2a at 2.1 A resolution (Fig. 5) . Electron densities of compounds 1, 18, and 19 are well defined and lead to no ambiguity regarding their orientations and positions in the ATP binding site. Commonly, the interaction between the 3 compounds and CK2 are mainly hydrophobic and involve mainly residues 53, 66, and 174. They use the plane formed by 2 adjacent cycles to fit perfectly into the "purine plane'' naturally occupied by the ATP adenine moiety (24, 36) . However, they differ in their orientation to conserve specific interactions between the common atoms of their scaffold and of the ATP groove. For instance, the common hydroxyl group (at position 9) of the 3 derivatives forms a direct hydrogen bond with the main chain nitrogen of Val 116 that mimics the classical ATP/CK2 interaction. But, the differences in geometry and orientation lead them to interact differently with the bottom of the binding pocket. Compound 1 fits into the ribose pocket and partially the a-phosphate site and interacts with the catalytic site via water molecules that connect N6 of compound 1 to the main chain of Asp 174 and the catalytic dyad (Lys68/Glu81). In addition, compound 1 is further stabilized by the external side of the ATP pocket by the mean of a p-interaction between its cycle D and the Histidine at position 160 (Supplementary Table S2 ). By contrast, compounds 18 and 19 are rotated by 180-degree rotation and binds deeply into the a-phosphate site to directly make a hydrogen bond between their nitrogen atom of chloropyridine group and Lys68 Nz atom.
Discussion
Despite many published CK2 inhibitors with various modes of inhibition (37, 38) , only few were successfully validated in vivo. In this work, first we report that pyridocarbazole and its angular analogues B[g/e]PI are in vitro potent submicromolar ATP-competitive CK2a inhibitors. Substitution requirements in pyridocarbazole derivatives are different for efficient inhibition of CK2 than substitution required for other known ellipticine targets (c-kit, topoisomerase IIa, DNA intercalation). This can give guidelines for compound optimization. Second, these compounds are also active on cellular CK2 kinase activity and induce cell cycle arrest of a glioblastoma cell line.
Proteins involved in the cells' suicide program such as ARC, Bid, and p53 (2) CK2 (39) . Indeed, we observed that in response to pyridocarbazole derivatives, HeLa cells showed caspase-dependent apoptosis. Cytotoxic effect may be partially due to CK2 inhibition because cytotoxicity appeared at concentrations lower than those required to achieve complete CK2a inhibition. Most of cancer cells rely, however, on high CK2 activity as judged from their susceptibility to CK2 inhibitors or silencing of CK2 catalytic subunits (40) . This undue reliance of tumor cells on CK2 activity may explain their high sensitivity to the pyridocarbazole derivatives. Another explanation is that these compounds target other cellular proteins such as prosurvival kinases. Indeed, kinase selectivity profiling of compound 18 showed that several kinases were significantly affected: Pim-1 and Mnk2, which are involved in cancer-related pathways (41) , and DRAK1, which is related to death-associated protein kinases that trigger apoptosis (42) . It is now accepted that high specificity is not a requisite for potent drugs (43) and that polypharmacology is an underlying mechanism essential in drug actions (43) . Indeed, hitting more than 1 kinase at once can prevent cells to bypass the primary target by activating redundant signaling pathways (44) . Interestingly, when assayed in a murine xenograft tumor growth assay, 1 of our compounds (18) exhibited antitumoral activity without apparent toxic effects. We conclude that this chemical class of leads seems to be safe enough to represent a good starting point for future optimization.
We have solved 3 CK2a-inhibitor complex structures. Crystal structure of CK2-compound 1 complex provides a clear explanation for the differential potency of various pyridocarbazole derivatives. The intolerance to any substitution except hydroxyl group at position 9 is fully explained by the crucial hydrogen bond that compound 1 makes with CK2a backbone, and that mimics interactions between ATP and CK2. However, the disruption of this crucial hydrogen bond can be partially compensated by extra interactions involving other residues as in compounds 14, 15, and 17, which bear polar groups either at position 1 or at position 2 and have residual inhibition capacity. Those groups would be there in favorable position to interact with CK2a residues Leu45 and His160. This is exemplified by the substitution in compound 16 , which bears a chlorine group as compound 15 and a hydroxyl group as compound 1, and retains full inhibition potency. However, in contrast to CK2a-compound 1 structure, the structures of CK2a in complex with compounds 18 and 19 revealed that their orientations are flipped by 180 degree, which lead their chlorine group to fit into the ATP cavity. Therefore, the position of such polar group cannot easily be predicted. Concerning position 11, reduction of this group volume by the substitution of a methyl group (in compound 1) by an atom of hydrogen (in compound 3) is correlated with a decreased inhibition (higher IC 50 ). This can be easily explained by the disruption of hydrophobic contacts between the methyl group and Met163 and Leu45 of CK2a. However, as the number of those contacts is in minority as compared with the overall network between compound 1 and CK2a, this disruption has a limited impact on IC 50 suggesting that position 11 would be tolerant to bulkier substituents. The structures of CK2a in complex with compounds 18 and 19 illustrate the ability of the CK2 ATP-binding groove to bind benzopyridoindole derivatives with "cycle'' configurations different from the original ellipticine, as long as they remain perfectly plane to fit into the purine plane. Furthermore, it appears crucial to keep the OH group at position 9 to mimic ATP/CK2 interaction as for compound 1. To conclude, this class of pyridocarbazole and benzopyridoindole derivatives has a well-mastered chemistry and displays new biological activities and good pharmacokinetic profile. Its high potency, the well-explored structure-activity relationship and the solved structure of these compounds in complex with CK2 will provide a good starting point for further optimization processes.
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